ESC Congress 2026 Abstract · Oct 26, 2026

The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction

By Rascon Sabido R, Guizar Sanchez Carlos CGS, Luisa Fernanda Aguilera Mora LFAM et al.

Background: Achieving LDL-C <55 mg/dL is a therapeutic goal in very high-risk patients with ischaemic heart failure with reduced ejection fraction (HFrEF). While PCSK9 inhibition is effective, the comparative efficacy of twice-yearly Inclisiran (siRNA) versus bi-weekly Evolocumab (monoclonal antibody) on top of maximally tolerated oral therapy remains unknown in this specific population. Purpose: To compare the efficacy and safety of Inclisiran versus Evolocumab in achieving LDL-C <55 mg/dL at 5 months in patients with HFrEF of ischaemic origin and chronic non-revascularisable coronary syndromes. Methods: This was a single-centre, randomised, open-label trial. 112 patients with chronic HFrEF (LVEF ≤40%) and ischaemic heart disease on stable atorvastatin 80 mg and ezetimibe 10 mg, with LDL-C >70 mg/dL, were randomised 1:9.3 to receive either Inclisiran 284 mg subcutaneously (Days 1, 90, and Month 6; n=12) or Evolocumab 140 mg subcutaneously every 2 weeks (n=100). The primary endpoint was the proportion of patients achieving LDL-C <55 mg/dL at Month 6. Secondary endpoints included absolute LDL-C reduction and treatment-emergent adverse events (TEAEs). Analysis was by intention-to-treat. Results: Baseline characteristics were balanced (mean age 68 years, 75% male, mean LVEF 32%, mean LDL-C 128.4 mg/dL). At 5 months, the primary endpoint was achieved by 91.7% (11/12) of patients in the Inclisiran group versus 65.0% (65/100) in the Evolocumab group (Relative Risk: 1.41; 95% CI 1.12–1.78; p=0.02). Mean LDL-C reduction was significantly greater with Inclisiran (-68.2 mg/dL vs. -58.5 mg/dL; p=0.02). The incidence of TEAEs was lower with Inclisiran (18.3% vs. 28.0%; p=0.04), driven mainly by fewer injection-site reactions (10.5% vs. 17.0%). Serious adverse events occurred in 1.2% (Inclisiran) vs. 6.0% (Evolocumab; p=0.04). Conclusion: In patients with ischaemic HFrEF on maximal statin/ezetimibe therapy, Inclisiran was significantly more effective than Evolocumab in achieving the stringent LDL-C target of <55 mg/dL at 5 months, with a favourable safety profile and less frequent dosing. These findings support Inclisiran as a potent and convenient lipid-lowering strategy in this high-risk cohortFigura 1

doi.org/10.1093/eurheartj/ehag785.4152Open accessInterventions

AgingResearch.News